Search Results

You are looking at 1 - 10 of 137 items for :

  • Refine by Access: All content x
Clear All
Open access

Irvin M Modlin, Harry Aslanian, Lisa Bodei, Ignat Drozdov, and Mark Kidd

Introduction The National Cancer Institute (NCI) Neuroendocrine Tumor (NET) Summit conference proceedings of 2008 identified that a critical unmet need in the management of NET disease was the absence of a sensitive and specific set of tumor

Open access

Matteo Scopel, Eugenio De Carlo, Francesca Bergamo, Sabina Murgioni, Riccardo Carandina, Anna Rita Cervino, Marta Burei, Federica Vianello, Vittorina Zagonel, Matteo Fassan, and Roberto Vettor

prevalence due to the more favorable prognosis ( 3 ). In Europe, the number of patients affected by NET in 2016 was estimated to be 292,971 ( 4 ). The skeletal system is a common site of metastasis for many solid tumors, but bone involvement by NETs has

Open access

Mark J C van Treijen, Catharina M Korse, Wieke H Verbeek, Margot E T Tesselaar, and Gerlof D Valk

-peptide PET/CT (DOTA-PET/CT), are used for risk stratification. Consequently, DOTA-PET/CT is currently one of the few diagnostics in NET disease with a strong impact on clinical management. Its diagnostic sensitivity is superior to anatomical imaging, leading

Open access

Ashley K Clift, Omar Faiz, Robert Goldin, John Martin, Harpreet Wasan, Marc-Olaf Liedke, Erik Schloericke, Anna Malczewska, Guido Rindi, Mark Kidd, Irvin M Modlin, and Andrea Frilling

Introduction Small bowel (SB) neuroendocrine tumours (NET) are accruing significant clinical attention due to their increasing incidence ( 1 , 2 ) in addition to recent advances in their molecular biology ( 3 , 4 , 5 , 6 ) and treatment

Open access

R C S van Adrichem, L J Hofland, R A Feelders, M C De Martino, P M van Koetsveld, C H J van Eijck, R R de Krijger, D M Sprij-Mooij, J A M J L Janssen, and W W de Herder

considered as important biochemical and pathological markers, respectively, for GEP NET clinical behaviour. The insulin-like growth factor (IGF) system has been suggested as an important regulator of GEP NET proliferation and differentiation (2) . Up to

Open access

Roxanne C S van Adrichem, Aart Jan van der Lely, Martin Huisman, Piet Kramer, Richard A Feelders, Patric J D Delhanty, and Wouter W de Herder

function of ghrelin in NETs is not well understood. It has been suggested that ghrelin could be responsible for the striking maintenance of body mass index (BMI) that can be observed in NET patients ( 15 , 28 ). Although total serum ghrelin levels in NET

Open access

Elham Barazeghi, Per Hellman, Gunnar Westin, and Peter Stålberg

give rise to carcinoid syndrome as a major cause of morbidity and mortality in approximately 20% of SI-NET patients. To date, genetic and epigenetic alterations in SI-NETs are poorly studied. Massive DNA sequencing analysis on SI-NETs revealed that

Open access

Katherine Van Loon, Li Zhang, Jennifer Keiser, Cendy Carrasco, Katherine Glass, Maria-Teresa Ramirez, Sarah Bobiak, Eric K Nakakura, Alan P Venook, Manisha H Shah, and Emily K Bergsland

with the National Comprehensive Cancer Network (NCCN) Oncology Outcomes Database, we identified all patients 18 years of age or older who presented to either UCSF or OSUMC for care of a NET on or after January 1, 2004 and before December 31, 2008

Open access

Carole Morin, Keo-Morakort Benedetto, Agathe Deville, Laurent Milot, Aurélie Theillaumas, Valérie Hervieu, Mathieu Pioche, Gilles Poncet, Julien Forestier, Laurent François, Francoise Borson-Chazot, Mustapha Adham, Catherine Lombard-Bohas, and Thomas Walter

initial characterizations and their management are varied and complex. Therefore, national ( 3 ) and international ( 4 , 5 , 6 ) guidelines were regularly updated to help physicians to optimize NEN management, both for neuroendocrine tumours (NET) and

Open access

Kazhan Mollazadegan, Britt Skogseid, Johan Botling, Tobias Åkerström, Barbro Eriksson, Staffan Welin, Anders Sundin, and Joakim Crona

–etoposide chemotherapy for panNEC (56%, n  = 49), than for panNET-G3 (0%, n  = 21) ( 9 ). Conversely, conventional treatments for WD-NET showed modest responses among NEC patients, with no objective responders among those receiving either everolimus ( n   = 25) ( 10